Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors

Tikva Allocell Pte. Ltd., a biotechnology firm based in Singapore, has successfully closed an $8 million Series A financing round led by Kantharos Capital. The funding, announced on July 22, 2026, is earmarked for advancing Tikva's engineered EBV-specific T-cell therapy, TAVST01, which targets B7-H3-positive solid tumors. This investment will facilitate the completion of Investigational New Drug (IND)-enabling activities and support a planned IND submission by the end of 2026.

Tikva Allocell specializes in developing allogeneic cell therapies for both adult and pediatric patients suffering from solid tumors. The company’s lead candidate, TAVST01, is designed to target B7-H3, a protein associated with a variety of challenging solid tumors, including those in the lung, breast, prostate, and pancreas. Unlike traditional donor-derived cell therapies, TAVST01 is built from Epstein-Barr virus (EBV)-specific T cells, which are naturally sustained by the body, thereby enhancing the therapy's potential effectiveness and longevity in the patient's immune system.

The strategic rationale behind this financing is rooted in Tikva's innovative approach to cell therapy. By utilizing EBV-specific T cells, Tikva aims to overcome the common pitfalls of conventional therapies, where donor cells often fail to persist due to immune rejection. TAVST01 is engineered to resist such rejection, allowing it to remain active in the patient’s body and potentially remodel the immunosuppressive tumor microenvironment that has historically limited the success of cell therapies in treating solid tumors. This unique mechanism positions Tikva to address a significant unmet need in oncology.

Kantharos Capital's investment reflects a strong belief in Tikva's scientific foundation and its leadership team. The firm, known for its long-term investment approach, sees potential in Tikva's ALLO SerpinB9 EBVST platform, which combines virus-specific T-cell technology with advanced protein-engineering strategies. This platform not only enhances the durability of the therapy but also minimizes the risk of graft-versus-host disease, a common complication in allogeneic therapies.

The successful fundraising round comes at a time when the biotechnology sector is increasingly focused on innovative treatments for solid tumors, an area that has seen limited advancements compared to hematological cancers. As Tikva prepares for its IND submission and subsequent clinical trials, the implications of this financing extend beyond the company itself, signaling a growing interest in next-generation cell therapies that could transform treatment paradigms for patients with solid tumors. The outcome of Tikva's clinical endeavors may pave the way for broader applications of engineered cell therapies, potentially reshaping the landscape of oncology treatment options.